Evidence map›Paper›PMID 42010355›Full record

ArticleCommunications biology2026

MCT4 deficiency suppresses tumor incidence and metastasis by downregulating IGF1 expression and enhancing anti-tumor immunity.

Shuo Wang, Hailing Guo, Lujin Feng, Xinyi Wang, Yujie Zhang, Xin Li, Xiaoju Zhou, Ningning Ma

Abstract read
In one paragraph

Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shuo WangWuya College of Innovation, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, China.ORCID http://orcid.org/0000-0002-6275-9675
Hailing GuoWuya College of Innovation, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, China.
Lujin FengWuya College of Innovation, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, China.
Xinyi WangWuya College of Innovation, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, China.
Yujie ZhangWuya College of Innovation, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, China.
Xin LiWuya College of Innovation, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, China.
Xiaoju ZhouSchool of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, China. zhouxiaoju@syphu.edu.cn.ORCID http://orcid.org/0009-0006-9590-7407
Ningning MaWuya College of Innovation, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, China. maningning@syphu.edu.cn.ORCID http://orcid.org/0009-0004-4907-4235

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monocarboxylate transporter 4 (MCT4/SLC16A3) is frequently upregulated in human cancers and associated with aggressive progression and poor clinical outcomes. To elucidate its functional role, we establish MCT4 homozygous knockout BALB/c mice (MCT4

Indexed as

Insulin-Like Growth Factor IMonocarboxylic Acid TransportersMuscle ProteinsNeoplasmsAnimalsDown-RegulationFemaleGene Expression Regulation, NeoplasticMacrophagesMiceMice, Inbred BALB CMice, KnockoutNeoplasm Metastasisinsulin-like growth factor-1, mouseInsulin-Like Growth Factor IMonocarboxylic Acid TransportersMuscle ProteinsSlc16a4 protein, mouse

Identifiers

PMID42010355
PMCPMC13096527

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.